Ignite Creation Date:
2024-05-05 @ 9:30 PM
Last Modification Date:
2024-10-26 @ 10:05 AM
Study NCT ID:
NCT00901849
Status:
COMPLETED
Last Update Posted:
2014-09-16
First Post:
2009-05-13
Brief Title:
TarcevaRapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 NF1
Sponsor:
Roger Packer
Organization:
Childrens National Research Institute
Study Overview
Official Title:
Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 NF1
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the feasibility of combining two drugs Tarceva an anti-EGFR agent and Rapamycin an mTOR inhibitor in children with progressive low-grade gliomas who have failed initial conventional treatment In addition to evaluating the toxicity of this drug regimen the potential efficacy of the regimen will be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None